Bertelmann, Thomas
Berndzen, Lars
Raber, Thomas
Pfeiffer, Sebastian
Leha, Andreas
Paul, Christoph
Feltgen, Nicolas
Bemme, Sebastian
Funding for this research was provided by:
Georg-August-Universität Göttingen
Article History
Received: 15 May 2021
Accepted: 1 December 2021
First Online: 16 December 2021
Competing interests
: Thomas Bertelmann is an employee of Novartis Pharma GmbH Nuremberg, Germany and a scientific staff member of the Department of Ophthalmology, University Medical Center Goettingen, Germany. He has received funding for research and clinical trials, consulting fees, honoraria, and travel reimbursement from Alcon, Alimera Sciences, Allergan, Bayer HealthCare, and Novartis. Lars Berndzen declares no conflict of interest. Thomas Raber is an employee of Oxurion NV, Leuven, Belgium. Nicolas Feltgen is a Consultant for Alimera Sciences, Novartis, and Roche as well as Speaker for Allergan, Alimera, Bayer, Heidelberg Engineering, Novartis, and Roche. Sebastian Pfeiffer, Andreas Leha, Christoph Paul and Sebastian Bemme declare no competing interests.